Skip to content

KLRS KLRS Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Amgen logo
AmgenAMGN
$559M+10.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$77.71M-8.7%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$666.7M+90.7%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+102%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's cash & equivalents?
KLRS (KLRS) reported cash & equivalents of $34.43M in Q1 2026.
How has KLRS's cash & equivalents changed year-over-year?
KLRS's cash & equivalents decreased by 65.9% year-over-year, from $100.97M to $34.43M.
What is the long-term trend for KLRS's cash & equivalents?
Over 4 years (2021 to 2025), KLRS's cash & equivalents has grown at a -16.5% compound annual growth rate (CAGR), from $201.66M to $98.05M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.